CHICAGO, Nov. 27, 2020 /PRNewswire-PRWeb/ -- Transpara, the leading Artificial Intelligence support system for breast cancer screening that uses deep learning algorithms to automatically detect potential breast cancer in 2D and 3D mammograms, has achieved another first in its class!
Transpara led the way being the first to use a unique scoring breast AI system for breast cancer risk. It is the first and remains the only DEEP LEARNING system to be FDA cleared for use on both 2D and 3D mammograms and now is first of its kind to help radiologists read more than 1 million mammograms.
"This is a major milestone in our mission to help radiologists improve survival rates for breast cancer, a disease that is growing relentlessly around the world," said Nico Karssemeijer, CEO for ScreenPoint Medical. "Despite the challenges presented by COVID in 2020, Transpara installations continue to prove successful in more and more countries."
"AI is obviously an important weapon being adopted to fight breast cancer even during these trying times. It is also becoming increasingly obvious that not all breast AI is the same. Our focus is to provide robust clinical evidence around the globe, and we can only do this with the help and support of our clinical partners. With this said, Transpara is being featured in an incredible 6 Scientific presentations with data from 5 different countries at this year's virtual RSNA."
"These studies for BOTH 2D AND 3D mammography look at how Transpara can improve accuracy, reduce interval cancers and help to reduce radiologist's workload. I'm not going to give the game away; you'll have to wait to listen to the presentations, but the results are powerful," said Professor Karssemeijer.
ScreenPoint Medical is also introducing new developments, including additional technology to ease integration of Transpara further in any mammography reading environment.
Here is the list of presentations at RSNA featuring Transpara:
A.J.T. Wanders, W. Mees, N. Janssen, A. Rodriguez-Ruiz, I. Sechopoulos, J.K. van Rooden, Ritse M. Mann. The potential of AI for improving early detection in breast cancer screening to reduce interval cancer rates
C. Balta, N. Janssen, A. Rodriguez-Ruiz, C. Mieskes, N. Karssemeijer, S. H. Heywang-Köbrunner. Using AI to triage which screening mammograms benefit from a double reading strategy
S. J. Vinnicombe, O. Parr, R. Sidebottom, D. Godden, E. Cornford, I. D. Lyburn. What impact could AI based computer aided detection have on the number and biological relevance of interval cancers in a population based screening programme?
C. Balta, N. Janssen, A. Rodriguez-Ruiz, C. Mieskes, N. Karssemeijer, S. H. Heywang-Köbrunner. Can AI help to increase the PPV of screen-recalled biopsies on calcifications?
M. Pinto, A. Rodriguez-Ruiz, K. Pedersen, S. Hofvind, R. Mann, S. Kappler, J. Wicklein, I. Sechopoulos. Impact of AI decision support on breast cancer screening interpretation with single-view wide-angle DBT
S. Romero Martín, J. Luis Raya Povedano, E. Elías Cabot, A. Gubern-Merida, A. Rodríguez-Ruiz, M. Álvarez Benito. Using autonomous AI to reduce the workload of breast cancer screening with breast tomosynthesis: a retrospective validation
Note to Editors
ScreenPoint Medical BV.
ScreenPoint Medical is the leading developer of AI driven image analysis technology which enables the automated reading of mammograms and digital breast tomosynthesis examinations.
Transpara® is an AI solution for breast cancer screening, that uses deep learning algorithms to automatically detect lesions suspicious for breast cancer in 2D and 3D mammograms. The software categorises mammograms on a 10-point scale indicating the risk that cancer is present. This Exam Score can be used to help radiologists prioritise patients for further investigation. Decision support marks for calcifications and soft tissue lesions are provided to support radiologists with image interpretation. Studies have shown that Transpara matches the performance of radiologists ,2,3, thus acting as a second opinion which increases diagnostic confidence and accuracy ,3. It is FDA cleared for 2D and 3D mammography.
ScreenPoint Medical was founded in 2014 by Professor Nico Karssemeijer and Professor Sir Michael Brady, two internationally respected experts in breast imaging, machine learning and computer aided detection. (diagnosis?)
The company's Head Office is in Nijmegen, The Netherlands.
1"Stand-alone artificial intelligence for breast cancer detection in mammography: Comparison with 101 radiologists", Rodriguez-Ruiz et al, JNCI: Journal of the National Cancer Institute, djy222, https://doi.org/10.1093/jnci/djy222, 2019
2"Detection of Breast Cancer with Mammography: Effect of an Artificial Intelligence Support System" Rodríguez-Ruiz et al, Radiology 290:2, 305-314, 2019.
3FDA approval number K193229
For more information, please email [email protected] or visit the website http://www.screenpoint-medical.com or http://www.transparabreastcare.com
Media Contact
David Lee, ScreenPoint Medical, +44 7470299318, [email protected]
Nicki Bryan, ScreenPoint Medical Inc, +14122085991, [email protected]
SOURCE ScreenPoint Medical
Share this article